|
Return to: College of Biological Sciences: Medical School: U of M Home |
|
|
|
|
||
 |
|||||||
 |
|||||||
 |
|||||||
|
|
||||||
 |
|||||||
|
|
||||||
 |
|||||||
|
Areas of Research Strength: Gene expression Cancer genetics Immunology Genetic diagnostics Mouse transgenics back to top |
||||||
|
|||||||
|
Research Techniques: Gene profiling (expression arrays, SNPs) Transfections Flow cytometry Transgenic mice PCR back to top |
||||||
|
|||||||
|
Research Interests: The research in the Van Ness lab is directed at defining genetic deregulation that contributes to lymphoid malignancies, particularly multiple myeloma. Multiple myeloma results from plasma cell expansion in the bone marrow, and unfortunately is very hard to treat. This difficulty comes in part from the variability in genetic and signaling pathways that are deregulated in the plasma cells as well as the cells in the bone marrow microenvironment. The lab is developing both cell lines and mouse models to explore how different genes can influence disease progression and therapeutic response. The lab is identifying some of the complexity of gene expression through microarray expression profiling; and we have undertaken a collaborative project to target gene deregulation that will contribute to models of plasma cell malignancy in the mouse. The Van Ness lab is also working with both national and international clinical groups to correlate genetic defects with disease outcome and response to different therapies. The ultimate goal is to contribute to genetic characterization of patients that will direct individualized therapy. back to top |
||||||
|
|||||||
|
Selected Publications: Kyle, RA, Leong, T, Li, S, Oken MM, Kay, NE, Van Ness, B, and Greipp, PR. (2006) Complete Response in Multiple Myeloma: An Eastern Cooperative Oncology Group Study. Cancer (in press). Cheung, WC, Kim, JS, Linden, M, Peng, L, Van Ness, B, Polakiewicz, RD, and Janz, S. (2005) The perils of abrogating myc-dependent apoptosis. CCR Frontiers in Science. 4:4-5. Linden, M, Kirchoff, N, Kvitrud, M, and Van Ness, B. (2004) Abl-myc retroviral infection elicits bone marrow plasma cell tumors in Bcl-xL transgenic mice. Leukemia Research. 4:435-444. Croonquist, P and Van Ness, B. (2005) The polycomb group protein Enhancer of Zeste Homologue 2 (EZH2) is an oncogene required for myeloma cell growth and the ras proliferative phenotype. Oncogene. 24:6269-6280. Linden, M, Kirchhof, N, Carlson, C, and Van Ness, B. (2004) Targeted overexpression of BCL-xL in B lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 103:2779-2790. Cheung, WC, Kim, JS, Linden, M, Van Ness, B. Polakiewicz, R, and Janz, S. Novel targeted deregulation of c-myc and bcl-xL combine to cause plasma cell malignancies in mice. (2004) J. Clinical Invest. 113: 1763-1773. Linden M, Kirchhof N, Carlson C and Van Ness B (2004) Targeted overexpression of BCL-xL in B lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood. 103: 2779-2790. Croonquist P, Linden M, Zhao F, and Van Ness B (2003) Gene Profiling of a Myeloma Cell Liine Reveals Similarities and Unique Signatures among IL-6 response, N-ras Activating Mutations and co-culture with bone Marrow Stromal Cells. Blood 2581-2592. Kyle, RA, et al...Van Ness, BG(The International Myeloma Working Group). (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. B J Hematol. 121:749-757. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4(6): 379-98. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M., Kyle, R., Dewald, G., Van Ness, B., Van Weir, S., Henderson, K., Bailey, R., and Greipp, P. (2003) Clinical and biological implications of recurrent genomic aberrations in myeloma. Blood. 101:4569-4575. Croonquist, P. Linden, M, Zhao, F, and Van Ness, B. (2003) Gene Profiling of a Myeloma Cell Line Reveals Similarities and Unique Signatures among IL-6 response, N-ras Activating Mutations and co-culture with Bone Marrow Stromal Cells. Blood. 2581-2592 Hu, L., Shi, Y., Hsu, J., Gera, J., Van Ness, B., and Lichtenstein, A. (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 101(8):3126-3135 Cheung,, W. and Van Ness, B. (2002) Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia. 16(6):1182-8 Rowley, M., and Van Ness, B. (2002) Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene 21:8679-8775. To view these and other publications visit http://www.ncbi.nlm.nih.gov/PubMed search menu should say PubMed type Van Ness B in the avaliable line back to top |
||||||
|
|||||||
|
Related Links: Bank On A Cure, with the International Myeloma Foundation BOAC SNP info Table (Excel) File back to top |
||||||
|
|||||||
 |
 |
| Bcl-xL transgenic mouse develops myeloma like bone disease |
 |
| Sternum of transgenic Bcl-xL transgenic mouse infiltrated with malignant plasma cells |
|
||||
|
